文献速递外周动脉疾病

基于注册研究评估紫杉醇药物涂层球囊血管成形术治疗股腘动脉支架内再狭窄

A registry-based study of paclitaxel drug-coated balloon angioplasty for the treatment of in-stent restenosis of the femoral-popliteal artery.
PubMed 文献 · J Vasc Surg · 2024-01-06

该前瞻性、非随机、多中心、单臂上市后注册研究在SVS VQI注册系统中43个中心纳入300例股腘动脉支架内再狭窄患者,评估IN.PACT Admiral紫杉醇药物涂层球囊的安全性和性能。12、24、36个月免于靶病变血运重建率分别为90%、72%、62%,技术成功率99%。作者认为结果优于文献报道的普通球囊血管成形术。

要点

  • 12、24、36个月免于靶病变血运重建率分别为90%、72%、62%。
  • 技术成功率99%,再支架置入率5%,溶栓率0.6%。
  • 12、24、36个月免于大截肢率分别为99.6%、98.9%、98.9%。

核心结论

  • 作者认为,该上市后注册研究显示紫杉醇药物涂层球囊治疗股腘动脉支架内再狭窄的结果优于文献报道的普通球囊血管成形术。
  • 作者认为结果展示了SVS VQI与产业界和联邦监管机构合作进行外周器械上市后评价的能力。

研究设计与样本

  • 前瞻性、非随机、多中心、单臂、上市后注册研究,评估IN.PACT Admiral药物涂层球囊治疗股浅动脉或腘动脉支架内再狭窄。
  • 2016年12月至2020年1月期间在SVS VQI注册系统的43个中心纳入300例患者,临床结局评估时间为12、24和36个月。
  • 主要终点为12个月靶病变血运重建,次要终点包括技术成功、靶血管血运重建、大截肢和全因死亡。

主要发现

  • 患者N=300,男性58%,平均年龄68±10岁,糖尿病56%,跛行80%,静息痛20%。
  • 病变位于股浅动脉68%、股浅动脉-腘动脉26%、腘动脉7%,平均病变长度17.8±11.8 cm,闭塞性病变43%(平均闭塞长度16±10 cm)。
  • TASC分型A 17%、B 29%、C 38%、D 15%;技术成功99%,再支架置入5%,溶栓0.6%。
  • Kaplan-Meier估计12、24、36个月免于靶病变血运重建率分别为90%、72%、62%;免于靶血管血运重建率分别为88%、68%、59%。
  • 12、24、36个月免于大截肢率分别为99.6%、98.9%、98.9%,生存率分别为95%、89%、85%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to report the results of a prospective, single-arm, registry-based study assessing the safety and performance of a paclitaxel drug-coated balloon (DCB) for the treatment of superficial femoral artery (SFA) or popliteal artery in-stent restenosis (ISR) in a United States population. METHODS: We conducted a prospective, non-randomized, multi-center, single-arm, post-market registry of the IN.PACT Admiral DCB for the treatment of ISR lesions in the SFA or popliteal artery at 43 sites within the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) Registry from December 2016 to January 2020. Clinical outcomes were assessed at 12, 24, and 36 months. The primary endpoint was target lesion revascularization at 12 months. Secondary endpoints included technical success, target vessel revascularization, major limb amputation, and all-cause mortality. Results are presented as survival probabilities based on Kaplan-Meier survival estimates. RESULTS: Patients (N = 300) were 58% male, with a mean age of 68 ± 10 years. Diabetes was present in 56%, 80% presented with claudication, and 20% with rest pain. Lesions included ISR of the SFA in 68%, SFA-popliteal in 26%, and popliteal arteries in 7%. The mean lesion length was 17.8 ± 11.8 cm. Lesions were categorized as occlusions in 43% (mean occluded length, 16 ± 10 cm). TASC type was A (17%), B (29%), C (38%), and D (15%). Technical success was 99%. Re-stenting was performed in 5% and thrombolysis in 0.6% of patients. Kaplan-Meier estimates for freedom from target lesion revascularization were 90%, 72%, and 62% at 12, 24, and 36 months. Freedom from target vessel revascularization was 88%, 68%, and 59% and freedom from major target limb amputation was 99.6%, 98.9%, and 98.9%, respectively, at 12, 24, and 36 months. Survival was 95%, 89%, and 85% at 12, 24, and 36 months. CONCLUSIONS: This post-market registry-based study shows promising results in treating femoral-popliteal ISR with paclitaxel DCB in comparison to the results of plain balloon angioplasty reported in the literature. These results demonstrate the ability of the SVS VQI to conduct post-market evaluation of peripheral devices in partnership with industry and federal regulators.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bertges DJ, Eldrup-Jorgensen J, Chaer RA, et al. A registry-based study of paclitaxel drug-coated balloon angioplasty for the treatment of in-stent restenosis of the femoral-popliteal artery. J Vasc Surg. 2024. PMID: 38190927. doi:10.1016/j.jvs.2023.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。